The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market size was estimated at USD 7,820 million in 2023 and is projected to reach USD 13,753.5 million in 2030 at a CAGR of 8.40% during the forecast period 2024-2030.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, progressive autoimmune disorder characterized by the inflammation of peripheral nerves, leading to demyelination, motor weakness, sensory loss, and in some cases, severe disability. It is considered the most common type of chronic acquired neuropathy and affects both adults and children. The exact cause of CIDP remains unclear, but it is thought to involve the body’s immune system mistakenly attacking its own nerves. Although CIDP is treatable with immunomodulatory therapies, its progressive nature and the potential for long-term disability without proper management highlight the importance of early diagnosis and sustained treatment regimens.
The market for CIDP treatments has seen significant growth in recent years, driven by increasing awareness of the disease, advancements in diagnostic methods, and a better understanding of the condition's pathophysiology. The scope of the CIDP market is largely determined by the number of diagnosed cases, which is estimated to range from 1 to 8 per 100,000 people globally, but many cases may remain undiagnosed or misdiagnosed. As healthcare systems improve in terms of access to specialized care, the potential for earlier diagnosis and more effective management increases, thereby expanding the market potential for pharmaceuticals and therapeutic solutions aimed at treating CIDP.
Several key trends are influencing the CIDP market, including the growing adoption of biologics, targeted therapies, and immunosuppressants in managing autoimmune conditions. Immunoglobulin therapies (IVIg) and corticosteroids are commonly used for symptomatic relief, while more recent treatments, such as monoclonal antibodies, are gaining traction. Additionally, there is increasing interest in precision medicine, as genetic and biomarker research provides new insights into CIDP subtypes and individual treatment responses. This shift towards personalized treatment approaches is enhancing the overall management of CIDP and creating opportunities for novel drug development.
The primary drivers of the CIDP market include the rising prevalence of autoimmune diseases, advancements in drug development, and an expanding pipeline of therapies. Increased research funding, improved patient awareness, and the development of specialized treatment centres are further supporting market growth. Additionally, the growing focus on improving the quality of life for CIDP patients and minimizing long-term disability through more effective treatment strategies are expected to contribute to market expansion. However, challenges such as high treatment costs, limited healthcare access in developing regions, and the need for better standardization in diagnosis and care may affect the market’s pace of growth.
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is driven by increasing awareness, advancements in diagnostic tools, and the growing adoption of targeted treatments such as immunoglobulin therapies and biologics. CIDP, a rare autoimmune disorder causing progressive nerve damage, is becoming more diagnosable as healthcare systems improve globally, expanding the potential market for treatments. Key trends include the shift towards precision medicine and personalized therapies, fuelled by genetic and biomarker research. The market is also supported by rising autoimmune disease prevalence and ongoing drug development, although challenges such as high treatment costs and limited healthcare access in certain regions may impact growth. As better treatments and earlier diagnosis emerge, the CIDP market is expected to continue expanding in the coming years.
North America to Dominate the Market
|
Report Feature |
Descriptions |
|---|---|
|
Growth Rate |
CAGR of 8.40% during the forecasting period, 2024-2030 |
|
Historical Data |
2020-2022 |
|
Forecast Years |
2024-2030 |
|
Base Year |
2023 |
|
Units Considered |
Revenue in USD million and CAGR from 2024 to 2030 |
|
Report Segmentation |
Treatment, Diagnosis, Route of administration, End-users, Distribution channel and Region. |
|
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
|
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East, and Africa |
|
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, and South Africa (50+ Countries Across the Globe) |
|
Companies Profiled |
F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Lilly, Amgen Inc., Actelion Pharmaceuticals Ltd. |
|
Available Customization |
In addition to the market data for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements. |
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market is segmented into various segments such as Treatment, Diagnosis, Route of administration, End-users, Distribution channel and Region:
Based on Treatment
Based on Diagnosis
Based on Route of Administration
Based on End-Users
Based on Distribution Channel
Based on region
The prominent players in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market are
.png)
.png)
.png)
.png)
.png)
.png)